Copy to clipboard 
ORTHOWORLD estimates Smith & Nephew (SNN) 2Q18 orthopaedic revenue of US $870.8MM, +4.4% from 2Q17, and 1H18 revenue of $1,736.1MM, +4.5% vs. 1H17.
ORTHOWORLD estimates for segment growth follow.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Reconstruction | $435.9 | $417.9 | $18.1 | 4.3% |
| Hip | $156.0 | $150.0 | $6.0 | 4.0% |
| Knee | $266.5 | $254.0 | $12.5 | 4.9% |
| Extremities | $13.4 | $13.8 | -$0.4 | -3.1% |
| Trauma | $108.8 | $113.2 | -$4.3 | -3.8% |
| Arthroscopy/Soft Tissue | $326.0 | $303.0 | $23.0 | 7.6% |
| Total | $870.8 | $834.0 | $36.7 | 4.4% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Reconstruction | $871.5 | $834.9 | $36.6 | 4.4% |
| Hip | $311.0 | $302.0 | $9.0 | 3.0% |
| Knee | $533.9 | $505.9 | $28.0 | 5.5% |
| Extremities | $26.6 | $26.9 | -$0.3 | -1.2% |
| Trauma | $216.6 | $220.1 | -$3.4 | -1.6% |
| Arthroscopy/Soft Tissue | $648.0 | $606.0 | $42.0 | 6.9% |
| Total | $1,736.1 | $1,660.9 | $75.2 | 4.5% |
ORTHOWORLD’s estimated revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $426.7 | $850.7 |
| Ex-U.S. | $444.1 | $885.4 |
In an upbeat and energizing first earnings call for Mr. Namal Nawana, the new CEO, much observation was made about opportunities in growth potential and flatter leadership, to which we’ll return in a moment.
Strong growth in Arthroscopy/Soft Tissue Repair continues with the REGENETEN bioinductive rotator cuff implant performing ahead of expectations. Notably, manufacturing operations are expanding to deal with demand for REGENETEN. Actions are in place to stabilize Arthroscopic Enabling Technologies’ mechanical resection segment, specifically focusing on the WEREWOLF Coblation system.
Trauma faced a tough comp in the Middle East in 2Q17, but the EVOS SMALL plate contributed to strong plate/screw performance and is expected to continue along that vein in 2H18.
Joint Recon was supported by a renewed focus on the POLAR3 total hip in the U.S. and buoyed by standby knee products, JOURNEY II, LEGION and ANTHEM. The robotic-assisted NAVIO system, used in partial and total knee applications, was noted as having a strong U.S. quarter—but no more specific detail than that.
Returning to leadership, Mr. Nawana has brought in two new appointments “from outside,” adding Mr. Mark Gladwell as President, Global Operations and Ms. Melissa Guerdan, to lead QA/RA.
On the salesforce: “They’re actually reasonably focused in their own areas; I don’t anticipate there needs to be a lot of change in order to have them calling on the right customers and with the portfolios we currently have.”
And on priorities: “To get more of our portfolio growing at or better than market.” He reiterated multiple times that “We may not always be the market leader, but where we have technology, we can provide leadership.” A positive message following a very active first three months on the job.
Source: Smith & Nephew; ORTHOWORLD Inc. estimates
ORTHOWORLD estimates Smith & Nephew (SNN) 2Q18 orthopaedic revenue of US $870.8MM, +4.4% from 2Q17, and 1H18 revenue of $1,736.1MM, +4.5% vs. 1H17.
ORTHOWORLD estimates for segment growth follow.
Q18
Q17
$ Change
% Change
...
ORTHOWORLD estimates Smith & Nephew (SNN) 2Q18 orthopaedic revenue of US $870.8MM, +4.4% from 2Q17, and 1H18 revenue of $1,736.1MM, +4.5% vs. 1H17.
ORTHOWORLD estimates for segment growth follow.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Reconstruction | $435.9 | $417.9 | $18.1 | 4.3% |
| Hip | $156.0 | $150.0 | $6.0 | 4.0% |
| Knee | $266.5 | $254.0 | $12.5 | 4.9% |
| Extremities | $13.4 | $13.8 | -$0.4 | -3.1% |
| Trauma | $108.8 | $113.2 | -$4.3 | -3.8% |
| Arthroscopy/Soft Tissue | $326.0 | $303.0 | $23.0 | 7.6% |
| Total | $870.8 | $834.0 | $36.7 | 4.4% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Reconstruction | $871.5 | $834.9 | $36.6 | 4.4% |
| Hip | $311.0 | $302.0 | $9.0 | 3.0% |
| Knee | $533.9 | $505.9 | $28.0 | 5.5% |
| Extremities | $26.6 | $26.9 | -$0.3 | -1.2% |
| Trauma | $216.6 | $220.1 | -$3.4 | -1.6% |
| Arthroscopy/Soft Tissue | $648.0 | $606.0 | $42.0 | 6.9% |
| Total | $1,736.1 | $1,660.9 | $75.2 | 4.5% |
ORTHOWORLD’s estimated revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $426.7 | $850.7 |
| Ex-U.S. | $444.1 | $885.4 |
In an upbeat and energizing first earnings call for Mr. Namal Nawana, the new CEO, much observation was made about opportunities in growth potential and flatter leadership, to which we’ll return in a moment.
Strong growth in Arthroscopy/Soft Tissue Repair continues with the REGENETEN bioinductive rotator cuff implant performing ahead of expectations. Notably, manufacturing operations are expanding to deal with demand for REGENETEN. Actions are in place to stabilize Arthroscopic Enabling Technologies’ mechanical resection segment, specifically focusing on the WEREWOLF Coblation system.
Trauma faced a tough comp in the Middle East in 2Q17, but the EVOS SMALL plate contributed to strong plate/screw performance and is expected to continue along that vein in 2H18.
Joint Recon was supported by a renewed focus on the POLAR3 total hip in the U.S. and buoyed by standby knee products, JOURNEY II, LEGION and ANTHEM. The robotic-assisted NAVIO system, used in partial and total knee applications, was noted as having a strong U.S. quarter—but no more specific detail than that.
Returning to leadership, Mr. Nawana has brought in two new appointments “from outside,” adding Mr. Mark Gladwell as President, Global Operations and Ms. Melissa Guerdan, to lead QA/RA.
On the salesforce: “They’re actually reasonably focused in their own areas; I don’t anticipate there needs to be a lot of change in order to have them calling on the right customers and with the portfolios we currently have.”
And on priorities: “To get more of our portfolio growing at or better than market.” He reiterated multiple times that “We may not always be the market leader, but where we have technology, we can provide leadership.” A positive message following a very active first three months on the job.
Source: Smith & Nephew; ORTHOWORLD Inc. estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
